Business & Investment

Profound medical institution announces third quarter 2021 financial results on November 4 – conference call

Article content

Toronto, October 18, 2021 (GLOBE NEWSWIRE) — Profound Medical Co., Ltd. (NASDAQ: PROF; TSX: PRN) (“Profound” or “Company”) is a commercial medical device company that develops and sells customizable, incision-free therapies for excision of diseased tissue, 2021 It will be announced in the third quarter of the year. Financial results after market closure on Thursday, November 4, 2021.

Profound management will hold a telephone conference at 4:30 pm Eastern Standard Time to review financial results and discuss business development during that period.

Article content

Results for the third quarter of 2021 Conference call details:
date: Thursday, November 4, 2021
time: 4:30 pm (Eastern Standard Time)
Live call: 1-800-773-2954 (Canada and the United States)
1-847-413-3731 (International)
Meeting ID: 50245581

Calls will be broadcast live and archived on our website. www.profoundmedical.com Under “Webcast” in the Investors section.

About Profound Medical Co., Ltd.

Profound is a commercial medical device company that develops and sells customizable, incision-free therapies for excision of lesioned tissue.

Profound has commercialized TULSA-PRO ® , Real-time MRI, robot-driven transurethral ultrasound, and closed-loop temperature feedback control. TULSA-PRO ® Is designed to provide surgeon-defined, customizable and predictable radiation-free ablation of prostate volume while actively protecting the urethra and rectum to maintain the patient’s natural functional capacity. .. TULSA-PRO ® Potential flexible technology for customizable prostatectomy, including mid-term cancer, localized radiation recurrent cancer, retention of locally advanced prostate cancer and hematuria relief, and transitional zones of massive benign prostatic hyperplasia (BPH) there is. TULSA-PRO ® It bears the CE mark, is approved by Health Canada, and is 510 (k) approved by the US Food and Drug Administration (“FDA”).

Article content

Profound has also commercialized Sonalleve ® An innovative treatment platform with the CE mark for the treatment of uterine fibroids and the treatment of palliative pain in bone metastases.Sonarive ® In addition, the non-invasive treatment of uterine fibroids has been approved by the National Medical Products Bureau of China, and the treatment of osteoid osteoma has been approved by the FDA under the humanitarian device exemption. We are in the early stages of exploring additional potential therapeutic markets for Sonarive. ® This technique has been shown to have clinical applications such as non-invasive resection of abdominal cancer and hyperthermia for the treatment of cancer.

Description of future prospects

Article content

This release contains forward-looking statements about Profound and its business. This includes, but is not limited to, expectations for the effectiveness of Profound’s technology in the treatment of prostate cancer, uterine fibroids, palliative pain, and osteoid osteoma. Often, but not always, forward-looking statements are “planned,” “expected,” “expected,” “planned,” “intended,” “intended,” and “expected.” “Do”, “believe”, “suggest” or variation (including negative variations) of such words or phrases, or “potential”, “possible”, or result of a particular action, event, or result. Occurs or is achieved, stating “is”, “possible”, “possible”, or “possible”. Such statements are based on the current expectations of Profound’s management. The future events and situations described in this release may or may not occur by a specific date and may or may not occur at all, known and unknown risks affecting the company, such as medical device industry, regulatory risks, etc. It can vary significantly as a result of factors and uncertainties. Approval, redemption, economic factors, general stock markets, and risks associated with growth and competition. Profound sought to identify key factors that could cause actual behavior, events, or outcomes to differ materially from those described in the forward-looking statements, but the behaviors, events, or outcomes are expected, estimated. , Or there may be other factors that cause it to be different from what you intended. We cannot guarantee any forward-looking statements. In addition, there are uncertainties about the spread of the COVID-19 virus and its impact on Profound’s business, its product demand, global supply chain, and general economic activity. Unless required by applicable securities law, forward-looking statements are only stated as of the date they were created, and is Profound the result of new information, future events? Regardless, we undertake no obligation to publicly update or revise any forward-looking statement. Or, unless required by law.

For more information, please contact:

Stephen Kilmer
Public relations activities for investors
skilmer@profoundmedical.com

T: 647.872.4849

Primary logo

Profound medical institution announces third quarter 2021 financial results on November 4 – conference call

https://financialpost.com/globe-newswire/profound-medical-to-release-third-quarter-2021-financial-results-on-november-4-conference-call-to-follow Profound medical institution announces third quarter 2021 financial results on November 4 – conference call

Back to top button